Innovotech Inc.

Innovotech Inc.

November 23, 2011 08:00 ET

Innovotech Reports Third Quarter 2011 Financial Results

EDMONTON, ALBERTA--(Marketwire - Nov. 23, 2011) - Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product development, today announced its unaudited financial and operational results for the three and nine-month periods ended September 30, 2011.


  • Initial revenue from veterinary product sales
  • Exclusive worldwide rights granted to Spectrum Labs Inc. to market Innovotech's veterinary biofilm tests
  • Private placement receives final approval from TSX Venture Exchange
  • Significant advances in Agress® chemistry which will be used to support its registration

"This quarter saw the start of a number of initiatives that have the potential to provide increasing revenue on an ongoing basis," said Ken Boutilier, President and Chief Executive Officer of Innovotech. "While Innovotech will continue to seek opportunities to advance products that are currently in its pipeline, our focus will be foremost on the progression of products that have the greatest and most immediate revenue potential."

During the third quarter, Innovotech granted exclusive worldwide rights to Spectrum Labs Inc., specialists in veterinary testing in the United States and over 40 countries worldwide, to market Innovotech's InnovoSCEPT veterinary biofilm tests as part of its testing service. With the launch of this service and Innovotech's continued promotion of its human testing service to doctors and potential patients, product sales increased during the quarter.

Innovotech also received final acceptance from the TSX Venture Exchange for a non brokered private placement for gross proceeds in excess of $800,000. Innovotech intends to use the proceeds from the offering to support marketing of its veterinary and human test kits and to support efforts to gain regulatory approval of its agricultural industry products.

Significant progress was made by the Company in the third quarter of 2011 in the area of Agress® chemistry, which will be used to support its registration. Work is underway to finalize protocols for a product chemistry package to be submitted to the EPA.

Financial Summary

Three-month period ended September 30 , Three-month period ended September 30 , Nine-month period ended September 30 , Nine-month period ended September 30 ,
($) 2011 2010 2011 2010
Revenues 393,970 425,051 825,428 1,287,709
G&A 335,876 332,185 890,199 992,083
R&D 250,549 235,317 753,126 626,580
Net loss (189,199 ) (240,998 ) (843,048 ) (732,908 )
Share Price $ 0.70 $ 0.55 $ 0.70 $ 0.55
Cash position 544,062 935,513 544,062 935,513


In the three-month period ended September 30, 2011, total revenues were $393,970 (2010 - $425,051; 2009 - $399,728). This included contract research revenue of $327,614 (2010 - $395,332; 2009 - $381,292) and product sales of $66,356 (2010 - $29,719; 2009 - $18,436). While revenue from contract research increased in the third quarter in comparison to revenue from the first and second quarters, overall contract research revenue for the nine-month period is still less than that for the same period in fiscal 2010. Product sales, however, were higher for the nine-month period than for the same period in the past three years. In the nine-month period ended September 30, 2011, total revenues were $825,428 (2010 - $1,287,709; 2009 - $989,425).

General and Administrative Expense

In the three-month period ended September 30, 2011, general and administrative expense, including stock based compensation expense and allocated amortization expense, was $335,876 (2010 - $332,185). The increase was mainly due to the loss on disposal of an abandoned asset for which no proceeds were received. In the nine-month period ended September 30, 2011, general and administrative expenses were $890,199 (2010 - $992,083). The decrease over the nine-month period was mainly attributable to reduced expenses for legal and other professional services and improved management of foreign exchange transactions.

Research and Development

In the three-month period ended September 30, 2011, research and development expense, including allocated amortization, was $250,549 (2010 - $235,317). The cost was partially offset by various grants of $118,374 (2010 - $87,523). The increase in research and development expense is directly related to increased development costs of a new family of products in human and veterinary susceptibility testing and extensive chemistry work on Agress®. In the nine-month period ended September 30, 2011, research and development expense was $753,126 (2010 - $626,580) offset by various grants of $364,961 (2010 - $129,099).

Liquidity and Capital Resources

At September 30, 2011, the Company had $544,062 in cash compared to $766,758 at December 31, 2010. Continued investment in development and marketing of two of the Company's lead products have contributed to a decrease in cash reserves since December 31, 2010. These expenditures were partially offset by the proceeds from the private placement initiated during the second quarter, as well as by cash inflows from product sales, contract research revenue and various grants.

Innovotech's third quarter 2011 Financial Statements and Management's Discussion and Analysis will be filed on The System for Electronic Document Analysis and Retrieval (SEDAR) at

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay™, bioFILM PA™ and InnovoSCEPT veterinary kits. The MBEC Assay™ is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA™ is the first diagnostic test to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for infections in both large and small animals.

Innovotech also has three products in advanced stages of development; InnovoSCEPT human tests have been designed specifically to address antibiotic treatment for human infections, Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and Sani-Lux™ is a light-activated, natural hard surface sanitizer.


This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information